We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Preclinical evaluation reveals BET protein inhibition downregulates miR-33a in CMML, suggesting synergistic therapeutic efficacy with PIM inhibitors.
Raw RNAseq data corresponding to Figures 2C, 4D and Supplemental Figure 2B
No takes yet. Share an insight, caveat, or question.
Letson et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: